期刊文献+

胃肠间质瘤危险性分级与哺乳动物雷帕霉素靶蛋白和磷酸化哺乳动物雷帕霉素靶蛋白表达的关系 被引量:1

Relationship between the risk grade of gastrointestinal stromal tumor and expression of mammalian target of rapamycin and phosphorylated mammalian target of rapamycin
下载PDF
导出
摘要 目的研究胃肠间质瘤危险性分级与磷脂酰肌醇3激酶(PI3K)/蛋白激酶(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)信号传导通路中mTOR和磷酸化哺乳动物雷帕霉素靶蛋白(p-mTOR)表达的关系。方法用免疫组织化学法检测40例胃肠间质瘤中PI3K/Akt/mTOR信号传导通路相关蛋白mTOR和p-mTOR的阳性表达率,分析其在不同危险程度组之间的差异。结果 mTOR、p-mTOR蛋白在部分胃肠间质瘤呈阳性表达,定位于细胞质。mTOR、p-mTOR在极低和低度危险组的阳性表达率均低于中高度危险组,差异均有统计学意义(P<0.05)。结论胃肠间质瘤PI3K/Akt/mTOR信号传导通路中mTOR和p-mTOR与其侵袭危险性有关,提示该信号传导通路在介导胃肠间质瘤发生、发展过程中起重要作用。 Objective To explore the relationship between the risk grade of gastrointestinal stromal tumor(GIST) and the expression of mammalian target of rapamycin ( mTOR ) and phosphorylated mammalian target of rapamycin ( p-mTOR ) in signal transduction pathway of phosphatidylinositol 3-hydroxy kinase/protein kinase B/mTOR (PI3K/Akt/mTOR). Methods The positive expression rates of PI3K/Akt/mTOR signal transduction pathway associated protein of mTOR, p-mTOR in 40 patients with GIST was detected by the immunohistochemistry staining. Results The mTOR and p-mTOR were positive ex- pression in some GIST patients and them were localized in the cytoplasm. The positive expression rates of mTOR and p-mTOR in very low-risk and low-risk group were significantly lower than those in intermediate-risk and high-risk group ( P 〈 0.05 ). Conclusion There expression of PI3K/Akt/mTOR signal transduction pathway associated protein of mTOR, p-mTOR is relat- ed to risk grade. It suggested that this signal transduction pathway may play an important role in the development process in GIST.
出处 《新乡医学院学报》 CAS 2013年第2期98-100,共3页 Journal of Xinxiang Medical University
基金 湖北省教育厅科学研究计划项目(编号:2009-381) 湖北省卫生厅科研项目(编号:2009JX4C15)
关键词 哺乳动物雷帕霉素靶蛋白 磷酸化哺乳动物雷帕霉素靶蛋白 危险性级别 胃肠间质瘤 mammalian target of rapamycin phosphorylated mammalian target of rapamycin risk grade gastrointestinal stromal tumor
  • 相关文献

参考文献11

  • 1Rhodes N, Heerding D A, Duckett D R,et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity [ J ]. Cancer Res,2008,68 (7) :2366-2374.
  • 2中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].中华胃肠外科杂志,2012,15(3):301-307. 被引量:117
  • 3Joensuu H. Risk stratification of patients diagnosed with gastroin- testinal stromal tumor [ J ]. Human Pathol, 2008,39 ( 10 ) : 1411- 1419.
  • 4王永霞,王金祥.人脑胶质瘤中核转录因子-κB p65和基质金属蛋白酶-9的表达及临床意义[J].新乡医学院学报,2012,29(6):425-427. 被引量:5
  • 5Lung S A, Ganmann A, Kcehl G E, et al. Mammalian target of ra- pamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model[ J]. lnt J Cancer,2007,120 (8) :1803-1810.
  • 6Zhang H B, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR[ J]. J Clin Invest ,2007,117 ( 3 ) :730-738.
  • 7Brugge J, Hung M C, Mills G B. A new mutational Akt activation in the PI3K pathway[J]. Cancer Cell,2007,12(2) :104-107.
  • 8Dematteo R P, Gold J S, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of pri- mary gastrointestinal stromal tumor(GIST) [ J ]. Cancer, 2008,112 (3) :608-715.
  • 9Anu G, Srirupa R, Alexander J F, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST) [ J ]. Proc Natl Acad Sci ,2010,107 ( 32 ) : 14333-14338.
  • 10Miettinen M, Wang Z F, Sarlomo-Rikala M, et al. Suecinate dehy- drogenase-deficient GISTS : a cliniepathology, immunohistoehemi- eal,and molecular genetic study of 66 gastric GISTS with predi- lection to young age[J].Am JSurg Pathol,2011,35(11 ) :1712- 1721.

二级参考文献60

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2秦新裕,刘凤林.胃肠道间质瘤的研究进展与展望[J].中华普通外科杂志,2007,22(8):561-563. 被引量:34
  • 3何纯刚,陈利生,李君,张森,梁君林,曹云飞.胃肠道外间质瘤的临床特征、治疗与预后[J].中华普通外科杂志,2007,22(8):579-581. 被引量:14
  • 4Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004,under the auspices of ESMO. Ann Oncol, 2005,16(4) :566-578.
  • 5Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117(KIT). Mod Pathol, 2000, 13(10) : 1134 -1142.
  • 6Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002,33(5) :459-465.
  • 7Agaimy A, Markl B, Arnholdt H, et al. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch, 2009,455(2) : 101-108.
  • 8Miettinen M, Lasota J. KIT(CD117): areview on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol, 2005,13(3) :205-220.
  • 9Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004,22(18) : 3813-3825.
  • 10Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008,39 (10) : 1411- 1419.

共引文献123

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部